Complement receptors in HIV infection

Immunological Reviews

Volumn 159, Issue , 1997, Pages 49-67

  Speth, Cornelia ^a   Kacani, Laco ^a   Dierich, Manfred P ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Institute for Hygiene and Social Medicine   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; GLYCOPROTEIN P 15095; RECEPTOR PROTEIN;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BRAIN; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOLYSIS; DENDRITIC CELL; ERYTHROCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH FOLLICLE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VERTICAL TRANSMISSION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0030664713     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01006.x     Document Type: Review

References (226)

1. Dierich MP, Ebenbichler CF, Marschang P, Fust G, Thielens NM, Arlaud GJ. HIV and human complement: mechanisms of interaction and biological implication. Immunol Today 1993;14:435-440.
2. Marschang P, et al. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS 1993;7:903-910.
3. Stoiber C, Clivio A, Dierich MP. Role of complement in HIV infection. Annu Rev Immunol 1997;15:649-674.
4. Solder BM, et al. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett 1989;22:135-145.
5. Spear GT, Landay AL, Sullivan BL, Dittel B, Lint TF. Activation of complement on the surface of cells infected by human immunodeficiency virus. J Immunol 1990;144:1490-1496.
6. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991;174:1417-1424.
7. Thieblemont N, Haeffner Cavaillon N, Weiss L, Maillet F, Kazatchkine MD. Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses 1993;9: 229-233.
8. Marschang P, et al. Complement activation by HIV-1-infected cells: the role of transmembrane glycoprotein gp41. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:102-109.
9. Thielens NM, Bally IM, Ebenbichler CF, Dierich MP, Arlaud GJ. Interaction of C1 with HIV-1. Behring Inst Mitt 1993;93:165-170.
10. Stoiber H, Thielens NM, Ebenbichler C, Arlaud GJ, Dierich MP. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 1994;24:294-300.
11. Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G. Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 1994;152:6028-6034.
12. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993;7:1307-1313.
13. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 1974;19:259-263.
14. Saarloos MN, Lint TF, Spear GT. Efficacy of HIV-specific and "antibody-independent" mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol 1995;99:189-195.
15. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993;67:53-59.
16. Wie X, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
17. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
18. Banapour B, Sernatinger J, Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986;152:268-271.
19. Yefenof E, Asjo B, Klein E. Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. Int Immunol 1991;3:395-401.
20. Dierich MP, Stoiber H, Clivio A. A "complement-ary" AIDS vaccine. Nat Med 1996;2:153-155.
21. Frank I, et al. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611-1620.
22. Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995;25:285-290.
23. Saifuddin M, et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995;182:501-509.
24. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996;183:307-310.
25. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35-58.
26. Meri S, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71:1-9.
27. Schmitz J, et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 1995;96:1520-1526.
28. Stoiber H, Schneider R, Janatova J, Dierich MP. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 1995;193:98-113.
29. Pinter C, Siccardi AG, Lopalco L, Longhi R, Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res Hum Retroviruses 1995;11: 971-980.
30. Fearon DT. Human complement receptors for C3b (CR1) and C3d (CR2). J Invest Dermatol 1985;85 (Suppl 1): 53S-57S.
31. Hinglais N, Kazatchkine MD, Mandet C, Appay MD, Bariety J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab Invest 1989;61:509-514.
32. Gray D, McConnell I, Kumararatne DS, MacLennan IC, Humphrey JH, Bazin H. Marginal zone B cells express CR1 and CR2 receptors. Eur J Immunol 1984;14:47-52.
33. Rodgaard A, Christensen LD, Thomsen BS, Wiik A, Bendixen G. Complement receptor type 1 (CR1, CD35) expression on peripheral T lymphocytes: both CD4- and CD8-positive cells express CR1. Complement Inflamm 1991;8:303-309.
34. Yaskanin DD, Thompson LF, Waxman FJ. Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell Immunol 1992;142:159-176.
35. Kumar V, Farries T, Swierkoz J, Atkinson JP. Translation of the human C3b/C4b receptor mRNA in a cell-free system and by Xenopus oocytes. Biochemistry 1989;28:4040-4046.
36. Waalen K, Forre O, Pahle J, Natvig JB, Burmester GR. Characteristics of human rheumatoid synovial and normal blood dendritic cells. Retention of class II major histocompatibility complex antigens and accessory function after short-term culture. Scand J Immunol 1987;26:525-533.
37. Reynes M, et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687-2694.
38. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membranes. Proc Natl Acad Sci USA 1979;76:5867-5872.
39. Sengelov H. Complement receptors in neutrophils. Crit Rev Immunol 1995;15:107-131.
40. Walsh GM, et al. Receptor expression and functional status of cultured human eosinophils derived from umbilical cord blood mononuclear cells. Blood 1990;76:105-111.
41. Fureder W, et al. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 1995;155:3152-3160.
42. Gasque P, et al. Identification and characterization of complement C3 receptors on human astrocytes. J Immunol 1996;156:2247-2255.
43. Sperr WR, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood 1994;84:3876-3884.
44. Fischer E, Appay MD, Cook J, Kazatchkine MD. Characterization of the human glomerular C3 receptor as the C3b/ C4b complement type one (CR1) receptor. J Immunol 1986;136:1373-1377.
45. Kasinath BS, Maaba MR, Schwartz MM, Lewis FJ. Demonstration and characterization of C3 receptors on rat glomerular epithelial cells. Kidney Int 1986;30:852-861.
46. Quigg RJ, Sneed AE III. Molecular characterization of rat glomerular epithelial cell complement receptors. J Am Soc Nephrol 1994;4:1912-1919.
47. Hogg N, Ross GD, Jones DB, Slusarenko M, Walport MJ, Lachmann PJ. Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol 1984;14:236-243.
48. Bieber T, Hanau D, Heid E, Kazatchkine MD. Histiocytosis-X cells express C3b, C3d, and C3bi receptor (CR1, CR2, and CR3) antigens. Arch Dermatol Res 1985;277:496-498.
49. Kai C, Okada N, Okada H. Expression of CR2 (C3d receptor) on the cell membranes of adult T cell leukemia. Jpn J Cancer Res 1988;79:805-808.
50. Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 1992;149:768-774.
51. Barnum SR. Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 1995;6:132-146.
52. Miyaguchi M, Uda H, Sakai S, Kubo T, Matsunaga T. Immunohistochemical studies of complement receptor (CR1) in cases with normal sinus mucosa and chronic sinusitis. Arch Otorhinolaryngol 1988;244:350-354.
53. Kasinath BS, Maaba MR, Schwartz MM, Lewis EJ. Demonstration and characterization of C3 receptors on rat glomerular epithelial cells. Kidney Int 1986;30:852-861.
54. Sixbey JW, Davis DS, Young LS, Hutt Fletcher L, Tedder TF, Rickinson AB. Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol 1987;68:805-811.
55. Springer TA, Galfre G, Secher DS, Milstein C. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. Eur J Immunol 1979;9:301-304.
56. McFarland HI, Nahill SR, Maciaszek JW, Welsh RM. CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 1992;149:1326-1333.
57. Brattig NW, Abakar AZ, Geisinger F, Kruppa TF. Cell-adhesion molecules expressed by activated eosinophils in Onchocerca volvulus infection. Parasitol Res 1995;81:398-402.
58. Fureder W, Agis H, Sperr WR, Lechner K, Valent P. The surface membrane antigen phenotype of human blood basophils. Allergy 1994;49:861-865.
59. Werfel T, Witter W, Gotze O. CD11b and CD11c antigens are rapidly increased on human natural killer cells upon activation. J Immunol 1991;147:2423-2427.
60. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol 1990;30:81-93.
61. Eikelenboom P, et al. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B-Cell Pathol Incl Mol Pathol 1991;60:329-336.
62. Palmer DG, Hogg N, Revell PA. Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involved by rheumatoid arthritis. A study with monoclonal antibodies. Pathology 1986;18:431-437.
63. Mangham DC, Scoones DJ, Drayson MT. Complement and the recruitment of mononuclear osteoclasts. J Clin Pathol 1993;46:517-521.
64. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest 1988;82:640-651.
65. Becker S, Daniel EG. Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990;129:351-362.
66. Vik DP, Fearon DT. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol 1987;138:254-258.
67. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-2127.
68. Unson CG, Erickson BW, Hugli TE. Active site of C3a anaphylatoxin: contributions of the lipophilic and orienting residues. Biochemistry 1984;23:585-589.
69. Fukuoka Y, Nielsen LP, Hugli TE. Characterization of receptors to the anaphylatoxins on isolated cells. Dermatologica 1989;179 (Suppl 1):35-40.
70. Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996;17:461-466.
71. del Balzo U, Polley MJ, Levi R. C3a-induced contraction of guinea pig ileum consists of two components: fast histamine-mediated and slow prostanoid-mediated. J Pharmacol Exp Ther 1989;248:1003-1009.
72. Wetsel RA. Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol Lett 1995;44:183-187.
73. Watanabe H, Kuraya M, Kasukawa R, Yanagisawa H, Yanagisawa M, Fujita T. Analysis of C5a receptor by monoclonal antibody. J Immunol Methods 1995;185:19-29.
74. Stimler Gerard NP, Galli SJ. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction. J Immunol 1987;138:1908-1913.
75. Tenner AJ, Cooper NR. Identification of cell types in human peripheral blood that binds C1q. J Immunol 1981;138:1174-1179.
76. Ghebrehiwet B, Silvestri L, McDevitt C. Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization. J Exp Med 1984;160:1375-1389.
77. Kuna P, Iyer M, Peerschke EI, Kaplan AP, Reid KB, Ghebrehiwet B. Human C1q induces eosinophil migration. Clin Immunol Immunopathol 1996;81: 48-54.
78. Peerschke EI, Ghebrehiwet B. Identification and partial characterization of human platelet C1q binding sites. J Immunol 1988;141:3505-3511.
79. Bordin S, Smith M, Ghebrehiwet B, Oda D, Page RC. Smooth muscle and epithelial cells express specific binding sites for the C1q component of complement. Clin Immunol Immunopathol 1992;63: 51-57.
80. Daha MR, Miltenburg AM, Hiemstra PS, Klar Mohamad N, Van Es LA, Van Hinsbergh VW. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro. Eur J Immunol 1988;18:783-787.
81. Bordin S, Page RC. Detection of a high-affinity binding site for the globular head regions of the C1q complement protein on a human diploid fibroblast subtype. Mol Immunol 1989;26:677-685.
82. Dykman TR, Cole JL, Iida K, Atkinson JP. Structural heterogeneity of the C3b/C4b receptor (Cr 1) on human peripheral blood cells. J Exp Med 1983;157:2160-2165.
83. Dykman TR, Hatch JA, Aqua MS, Atkinson JP. Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J Immunol 1985;134:1787-1789.
84. Schifferli JA, Ng YC, Paccaud JP, Walport MJ. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol 1989;75:329-335.
85. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.
86. Madi N, Paccaud JP, Steiger G, Schifferli JA. Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1). Clin Exp Immunol 1991;84:9-15.
87. Melchers F, Erdei A, Schulz T, Dierich MP. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 1985;317:264-267.
88. Arvieux J, Yssel H, Colomb MG. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 1988;65:229-235.
89. Tausk F, Gigli I. The human C3b receptor: function and role in human diseases. J Invest Dermatol 1990;94 (Suppl 6): 141S-145S.
90. Fallman M, Andersson R, Andersson T. Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles. J Immunol 1993;151:330-338.
91. Ernst JD, Rosales JL, Zimmerli S. Calcium signalling initiated by CR1 (CD35) crosslinking is mediated by phagocyte Fc gamma receptors in cis. Biochem Biophys Res Commun 1995;209: 1032-1038.
92. Mathew JM, Naziruddin B, Duffy B, Krych M, Mohanakumar T. Functional analysis of complement receptor 1 using a new monoclonal antibody, KuN241. Hybridoma 1995;14:29-35.
93. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. Functional dissection of the CD21/ CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med 1993;178:1407-1417.
94. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med 1991;173:1083-1089.
95. Iida K, Nadler L, Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 1983;158:1021-1033.
96. Carter RH, Fearon DT. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J Immunol 1989;143:1755-1760.
97. Lowell CA, Klickstein LB, Carter RH, Mitchell JA, Fearon DT, Ahearn JM. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med 1989;170:1931-1946.
98. Nemerow GR, Houghten RA, Moore MD, Cooper NR. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 1989;56:369-377.
99. Mitomo K, Fujita T, Iida K. Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med 1987;165:1424-1429.
100. Sinclair AJ, Farrell PJ. Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol 1995;69:5461-5468.
101. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-149.
102. Pascual M, French LE. Complement in human diseases: looking towards the 21st century. Immunol Today 1995;16:58-61.
103. Matsumoto AK, Kopicky Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 1991;173:55-64.
104. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med 1993;178:1407-1417.
105. Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol 1990;144:1640-1645.
106. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med 1983;158:1785-1803.
107. Diamond MS, Garcia Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 1993;120:1031-1043.
108. Ueda T, Rieu P, Brayer J, Arnaout MA. Identification of the complement iC3b binding site in the beta 2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci USA 1994;91: 10680-10684.
109. Vetvicka V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996;98:50-61.
110. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996;156:1235-1246.
111. Zhou M, Todd RF III, van de Winkel JG, Petty HR. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc gamma receptor III on human neutrophils. Possible role of lectin-like interactions. J Immunol 1993;150:3030-3041.
112. Poo H, Krauss JC, Mayo Bond L, Todd RF III, Petty HR. Interaction of Fc gamma receptor type IIIB with complement receptor type 3 in fibroblast transfectants: evidence from lateral diffusion and resonance energy transfer studies. J Mol Biol 1995;247:597-603.
113. Xue W, Kindzelskii AL, Todd RF III, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994;152:4630-4640.
114. Bohuslav J, et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1998;181:1381-1390.
115. Zarewych DM, Kindzelskii AL, Todd RF III, Petty HR. LPS induces CD14 association with complement receptor type 3, which is reversed by neutrophil adhesion. J Immunol 1996;156:430-433.
116. Galon J, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol 1996;157:1184-1192.
117. Pettit EJ, Hallett MB. Pulsatile Ca2+ influx in human neutrophils undergoing CD11b/CD18 integrin engagement. Biochem Biophys Res Commun 1997;230: 258-261.
118. Valmu L, Autero M, Siljander P, Patarroyo M, Gahmberg CG. Phosphorylation of the beta-subunit of CD11/CD18 integrins by protein kinase C correlates with leukocyte adhesion. Eur J Immunol 1991;21:2857-2862.
119. Thieblemont N, Haeffner Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD. Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 1995;155:4861-4867.
120. Arnaout MA, Schwarting R, Warner NL, Ross GD. Lanier LL. p150/95, third member of the LFA-1/CR3 polypeptide family identified by anti-Leu M5 monoclonal antibody. Eur J Immunol 1985;15:713-718.
121. Kindzelskii AL, Xue W, Todd RF III, Boxer LA, Petty HR. Aberrant capping of membrane proteins on neutrophils from patients with leukocyte adhesion deficiency. Blood 1994;83:1650-1655.
122. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994;12:775-808.
123. Ghebrehiwet B. Functions associated with the C1q receptor. Behring Inst Mitt 1989;84:204-215.
124. Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 1996;93:2245-2252.
125. Spira AI, et al. Cellular targets of infection with and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-225.
126. + T cells, and AIDS. J Virol 1997;71:4016-4023.
127. Cameron PU, Forsum U, Teppler H, Granelli-Piperno A, Steinman RM. During HIV-1 infection most blood dendritic cells are not productively infected and can induce allogeneic CD4+ T cells clonal expansion. Clin Exp Immunol 1992;88:226-236.
128. Pope M, Gezelter S, Gallo N, Hoffman L, Steinman RM. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med 1995;182:2045-2056.
129. Frankel SS, et al. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 1996;272:115-117.
130. Patterson S, Knight SC. Susceptibility of human peripheral blood dendritic cells to infection by human immunodeficiency virus. J Gen Virol 1987;68:1177-1181.
131. De Panfilis G, Soligo D, Manara GC, Ferrari C, Torresani C. Adhesion molecules on the plasma membrane of epidermal cells. I. Human resting Langerhans cells express two members of the adherence-promoting CD11/CD18 family, namely, H-Mac-1 (CD11b/CD18) and gp 150,95 (CD11c/CD18). J Invest Dermatol 1989;93:60-69.
132. Delibrias CC, Kazatchkine MD, Fischer E. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 1993;38:183-189.
133. Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 1991;173:1151-1158.
134. Robinson WE Jr, Montefiori DC, Mitchell WM. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990;175:600-604.
135. Jiang SB, Lin K, Neurath AR. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med 1991;174:1557-1563.
136. Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 1992;149:768-774.
137. Mouhoub A, Delibrias CC, Fischer E, Boyer V, Kazatchkine MD. Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996;106:297-303.
138. Larcher C, et al. Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells. J Acquir Immune Defic Syndr 1990;3: 103-108.
139. Larcher C, Julen N, Prodinger WM, Totsch M, Gurtler L, Dierich MP. Reduced CD21 (CR2) and CD54 (ICAM-1) expression in MT2 cells with HIV-1 or HIV-2 strains. Immunol Lett 1995;46:31-36.
140. June RA, Landay AL, Stefanik K, Lint TF, Spear GT. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons. Immunology 1992;75:59-65.
141. Tausk FA, McCutchan A, Spechko P, Schreiber RD, Gigli I. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 1986;78:977-982.
142. Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990;162:1227-1232.
143. Pantaleo G, Fauci AS. Tracking HIV during disease progression. Curr Opin Immunol 1994;6:600-604.
144. Haase AT, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274:985-989.
145. Cohen OJ, Pantaleo G, Lam GK, Fauci AS. Studies on lymphoid tissue from HIV-infected individuals: implications for design of therapeutic strategies. Springer Semin Immunopathol 1997;18: 305-322.
146. Embretson J, et al. Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
147. Pantaleo G, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
148. Joling P, et al. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 1993;150:1065-1073.
149. Sellheyer K, Schwarting R, Stein H. Isolation and antigenic profile of follicular dendritic cells. Clin Exp Immunol 1989;78:431-436.
150. Schriever F, et al. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989;169:2043-2058.
151. Butch AW, Hug BA, Nahm MH. Properties of human follicular dendritic cells purified with HJ2, a new monoclonal antibody. Cell Immunol 1994;155:27-41.
152. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;386:529-534.
153. Knight SC, Patterson S. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu Rev Immunol 1997;15:593-615.
154. Heath SL, Tew G, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and HIV infectivity. Nature 1995;377:740-744.
155. Schwaeble W, et al. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 1995;155:4971-4978.
156. Turner RR, Levine AM, Gill PS, Parker JW, Meyer PR. Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. Am J Surg Pathol 1987;11:625-632.
157. Sprenger R, et al. Follicular dendritic cells productively infected with immunodeficiency viruses transmit infection to T-cells. Med Microbiol Immunol 1995;184: 129-134.
158. Legendre C, Gras G, Krzysiek R, Galanaud P, Richard Y, Dormont D. Mechanisms of opsonized HIV entry in normal B lymphocytes. FEBS Lett 1996;381:227-232.
159. Gras G, Richard Y, Roques P, Olivier R, Dormont D. Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993;81:1808-1818.
160. Boyer V, Delibrias C, Noraz N, Fischer E, Kazatchkine MD, Desgranges C. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol 1992;36:879-883.
161. Montefiori DC, Stewart K, Ahearn JM, Zhou J, Zhou J. Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 1993;67:2699-2706.
162. Fingeroth JD, Heath ME, Ambrosino DM. Proliferation of resting B cells is modulated by CR2 and CR1. Immunol Lett 1989;21:291-301.
163. Weiss L, Delfraissy JF, Vazquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol 1987;138:2988-2993.
164. Daha MR, Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol 1984;132:1197-1201.
165. Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 1986;233:1084-1086.
166. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-622.
167. Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency virus (HIV) infection. J Clin Immunol 1991;11:55-64.
168. Ellaurie M, Rubinstein A, Rosenstreich DL. IgE levels in pediatric HIV-1 infection. Ann Allergy Asthma Immunol 1995;75: 332-336.
169. Amadori A, De Rossi A, Faulkner-Valle GP, Chieco-Bianchi L. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin Immunol Immunopathol 1988;46: 342-351.
170. Amadori A, et al. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol 1989;143:2146-2152.
171. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 1995;154:483-490.
172. Kacani L, Stoiber H, Dierich MP. Role of IL-15 in HIV-associated hypergammaglobulinaemia. Clin Exp Immunol 1997;108:14-18.
173. Bajtay Z, Kacani L, Erdei A, Dierich MP. HIV-1 induces human monocyte-derived macrophages to produce complement component C3 and to fix C3 on their surface. J Leukoc Biol (In Press).
174. Kehrl JH, Rieckmann P, Kozlow E, Fauci AS. Lymphokine production by B cells from normal and HIV-infected individuals. Ann NY Acad Sci 1992;651:220-227.
175. + T cells to produce IL-4. J Immunol 1997;158:4171-4179.
176. Kosco-Vilbois H, Zentgraf H, Gerdes J, Bonnefoy J-Y. To "B" or not to "B" a germinal center? Immunol Today 1997;18:225-230.
177. Munson LG, Scott ME, Landay AL, Spear GT. Decreased levels of complement receptor 1 (CD35) on B lymphocytes in persons with HIV infection. Clin Immunol Immunopathol 1995;75: 20-25.
178. Reisinger EC, et al. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS 1990;4:961-965.
179. Thieblemont N, Haeffner Cavaillon N, Ledur A, L'Age Stehr J, Ziegler Heitbrock HW, Kazatchkine MD. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993;92:106-113.
180. Abbate I, et al. Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin. Arch Virol 1995;140:1849-1854.
181. Castilletti C, et al. HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses 1995;11: 547-553.
182. Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997;71:3588-3596.
183. Stoiber H, et al. Inhibition of HIV-1 replication in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol 1997 (In Press).
184. Stoiber H, Schneider R, Janatova J, Dierich MP. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 1995;193:98-113.
185. Würzner R, et al. Human immunodeficiency virus type 1 gp41 binds to Candida albicans via complement C3-like regions. J Infect Dis 1997(In press).
186. Pascual M, Danielsson C, Steiger G, Schifferli JA. Proteolytic cleavage of CR1 on human erythrocytes in vivo: evidence for enhanced cleavage in AIDS. Eur J Immunol 1994;24:702-708.
187. Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. J Infect Dis 1994;170:429-432.
188. Cohen JH, Geffriaud C, Caudwell V, Kazatchkine MD. Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS 1989;3:397-399.
189. Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD. Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987;1:89-94.
190. Van Dyne S, Holers VM, Lublin DM, Atkinson JP. The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;68:570-579.
191. Hatch WC, Pousada E, Losev L, Rashbaum WK, Lyman WD. Neural cell targets of human immunodeficiency virus type 1 in human fetal organotypic cultures. AIDS Res Hum Retroviruses 1994;10: 1597-1607.
192. Michaels J, Sharer LR, Epstein LG. Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. Immunodefic Rev 1988;1:71-104.
193. Watkins BA, et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science 1990;249:549-553.
194. Perry VH, Gordon S. Modulation of CD4 antigen on macrophages and microglia in rat brain. J Exp Med 1987;166:1138-1143.
195. Porwit A, et al. Cell association of HIV in AIDS-related encephalopathy and dementia. APMIS 1989;97:79-90.
196. Jordan CA, Watkins BA, Kufta C, Dubois Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991;65:736-742.
197. Peudenier S, Hery C, Ng KH, Tardieu M. HIV receptors within the brain: a study of CD4 and MHC-II on human neurons, astrocytes and microglial cells. Res Virol 1991;142:145-149.
198. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimers disease. Glia 1993;7:75-83.
199. He J, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997;385:645-649.
200. Hassan NF, Campbell DE, Rifat S, Douglas SD. Isolation and characterization of human fetal brain-derived microglia in in vitro culture. Neuroscience 1991;41:149-158.
201. Gehrmann J, Banati RB, Wiessner C, Hossmann KA, Kreutzberg GW. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? Neuropathol Appl Neurobiol 1995;21: 277-289.
202. Reid DM, Perry VH, Andersson PB, Gordon S. Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience 1993;56:529-533.
203. Nath A, Hartloper V, Furer M, Fowke KR. Infection of human fetal astrocytes with HIV-1: viral tropism and the role of cell to cell contact in viral transmission. J Neuropathol Exp Neurol 1995;54: 320-330.
204. Sharer LR, Saito Y, Epstein LG, Blumberg BM. Detection of HIV-1 DNA in pediatric AIDS brain tissue by two-step ISPCR. Adv Neuroimmunol 1994;4:283-285.
205. Tornatore C, Chandra R, Berger JR, Major EO. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 1994;44:481-487.
206. Blumberg BM, Gelbard HA, Epstein LG. HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis. Virus Res 1994;32:253-267.
207. Ma M, Geiger JD, Nath A. Characterization of a novel binding site for the human immunodeficiency virus type 1 envelope protein gp120 on human fetal astrocytes. J Virol 1994;68:6824-6828.
208. Ennas MG, et al. Immunocompetent cell markers in human fetal astrocytes and neurons in culture. J Neurosci Res 1992;32:424-436.
209. Benveniste EN. Cytokine circuits in brain. Implications for AIDS dementia complex. Res Publ Assoc Res Nerv Ment Dis 1994;72:71-88.
210. Yefenof E, Asjo B, Klein E. Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. Int Immunol 1991;3:395-401.
211. Ramos OF, Patarroyo M, Yefenof E, Klein E. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets. J Immunol 1989;142:4100-4104.
212. Ramos OF, Nilsson B, Nilsson K, Eggertsen G, Yefenof E, Klein E. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. Cell Immunol 1989;119:459-169.
213. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J Infect Dis 1993;167:905-911.
214. Muller F. Reactive oxygen intermediates and human immunodeficiency virus (HIV) infection. Free Radic Biol Med 1992;13:651-657.
215. Szelc CM, Mitcheltree C, Roberts RL, Stiehm ER. Deficient polymorphonuclear cell and mononuclear cell antibody-dependent cellular cytotoxicity in pediatric and adult human immunodeficiency virus infection. J Infect Dis 1992;166:486-493.
216. Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr 1990;117:531-540.
217. Pitrak DL, Tsai HC, Mullane KM, Sutton SH, Stevens P. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. J Clin Invest 1996;98:2714-2719.
218. Coxon A, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 1996;5:653-666.
219. Schwartz DA, Nahmias AJ. Human immunodeficiency virus and the placenta. Current concepts of vertical transmission in relation to other viral agents. Ann Clin Lab Sci 1991;21:264-274.
220. Douglas GC, King BF. Maternal-fetal transmission of human immunodeficiency virus: a review of possible routes and cellular mechanisms of infection. Clin Infect Dis 1992;15:678-691.
221. Toth FD, et al. Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 1994;96:389-394.
222. Hussain LA, Kelly CG, Rodin A, Jourdan M, Lehner T. Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium. Clin Exp Immunol 1995;102:384-388.
223. Connor E, et al. Acquired immunodeficiency syndrome-associated renal disease in children. J Pediatr 1988;113:39-44.
224. Kimmel PL, Phillips TM, Ferreira Centeno A, Farkas Szallasi T, Abraham AA, Garrett CT. HIV-associated immune-mediated renal disease. Kidney Int 1993;44:1327-1340.
225. Van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, Klar Mohamad N, van Es LA, Daha MR. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. J Am Soc Nephrol 1996;7:573-581.
226. Teixeira JE, Costa RS, Lachmann PJ, Wurzner R, Barbosa JE. CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients. Clin Exp Immunol 1996;105:497-503.